GlassScriptPhysician profile
Alexander Steven Burch
NPI 1396207361
$1,951.80
in general payments reported to CMS, 2019-2025
32 companies · $67.11 in 2025
The $67.11 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $737 · 2022: $282 · 2023: $466 · 2024: $400 · 2025: $67.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $336.32 | 2021-2022 | |
| Abbott Laboratories | $152.68 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $122.22 | 2021-2024 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $121.86 | 2024 | Inpefa |
| Xeris Pharmaceuticals, INC. | $110.49 | 2023-2024 | Gvoke Hypopen |
| Novo Nordisk INC | $102.12 | 2021-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $93.90 | 2021-2022 | |
| Glaxosmithkline, LLC. | $81.45 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.71 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $69.82 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $60.38 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.66 | 2024 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $46.99 | 2022-2025 | Zoryve, Seglentis, Livalo |
| Intuitive Surgical, INC. | $46.77 | 2023 | Da Vinci Surgical System |
| Exact Sciences Corporation | $44.25 | 2023-2025 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.76 | 2023-2024 | |
| Astellas Pharma US INC | $43.32 | 2021 | |
| Merck Sharp & Dohme LLC | $40.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $36.97 | 2022-2023 | |
| Hikma Pharmaceuticals USA | $28.56 | 2021 | |
| Eyevance Pharmaceuticals LLC | $28.56 | 2021 | |
| Paratek Pharmaceuticals, INC. | $28.32 | 2023 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $28.17 | 2023 | |
| Dexcom, INC. | $25.61 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $19.28 | 2021 | |
| Eisai INC. | $17.74 | 2021 | |
| Esperion Therapeutics, INC. | $16.68 | 2023 | Nexletol |
| Evoke Pharma, INC. | $15.65 | 2021 | |
| Philips North America LLC | $15.42 | 2024 | (Cm9) Amb Mon & Diag Und |
| Amgen INC. | $14.42 | 2024 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $14.30 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $13.75 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Burch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.